期刊文献+

HPLC测定甲磺酸伊马替尼 被引量:5

Determination of Imatinib mesylate by HPLC
原文传递
导出
摘要 目的建立HPLC法测定甲磺酸伊马替尼原料药的含量。方法采用ZorbaxSB—C18色谱柱(250mm×4.6mm,5μm),柱温30℃,流动相为乙腈-水-三乙胺(22:77:1,首先配制三乙胺水溶液,用85%磷酸调pH3.5),流速1.1mL·min-1,检测波长268nm,进样体积20μL。结果甲磺酸伊马替尼原料药5~500μg·mL-1与峰面积呈良好的线性关系(r=0.9999,n=10),检测限1ng·mL-1,平均回收率及RSD分别为99.82%、0.2%(n=9)。结论所用方法灵敏准确,可为甲磺酸伊马替尼原料药的质量控制提供试验依据。 OBJECTIVE To develop an HPLC method for the content determination in the raw material of Imatinib mesylate. METHODS An Zorbax SB -C18 column(250 mmx 4.6 mm ,5 μm)was used with a mobile phase of aeetonitrile -water- triethyl- amine(22 : 77 : 1 ), and the aqueous solution of triethylamine was adjusted to pH3.5. The detection wavelength was set at 268 nm, the column temperature was 30 ℃ ,and the flow rate was 1.1 mL.min-1. The injection volume was 20 μL. RESULTS The linear range of lmatinib mesylate was 5 - 500 μg mL- 1 (r= 0. 9999, n = 10). The detection limit for Imatinih mesylate was 1 ng. mL - 1. The average recovery of Imatinib mesylate was 99.82% ( RSD = 0.2% , n = 9 ). CONCLUSION The method is simple, reliable, accurate and very suitable, which can be used for the content determination of Imatinib mesylate.
出处 《华西药学杂志》 CAS CSCD 北大核心 2013年第6期626-628,共3页 West China Journal of Pharmaceutical Sciences
关键词 甲磺酸伊马替尼 含量测定 高效液相色谱法 Imatinib mesylate Determination HPLC
  • 相关文献

参考文献6

二级参考文献23

  • 1王晨.甲磺酸伊马替尼抗肿瘤作用的研究[J].天津药学,2005,17(4):63-66. 被引量:3
  • 2盛远见,于吉人.酪氨酸激酶抑制剂伊马替尼治疗胃肠道间质瘤临床研究进展[J].浙江医学,2006,28(1):76-78. 被引量:5
  • 3Ivanovic D, Medenica M, Jancic B, et al. Reversed - phase liquid chromatography analysis of imatinib rnesylate and impurity product in glivec capsules. J Chromatogr B,2004,800:253 被引量:1
  • 4ZHANG Rong(张榕).Micro Computer Polarography Analisys (微机极谱分析).Harbin(哈尔滨):Heilongjiang People’s Publishing House(黑龙江人民出版社),2002.77 被引量:1
  • 5Council of Europe. European Pharmacopeia Technical Guide for the Elaboration of Monographys. 3th Ed. Strasbourg : Cedex, 1999. 178 被引量:1
  • 6Ivanovic D, Medenica M, Jancic B, et al. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules [ J ]. Journal of Chromatography B,2004,800 : 253 - 8. 被引量:1
  • 7Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 Acid Glycoprotein Binds to Imatinib ( STI571 ) and Substantially Alters Its Pharmacokinetics in Chronic Myeloid Leukemia Patients. [ J]. Clinical Cancer Research,2003,9 ( 2 ) : 625 - 32. 被引量:1
  • 8Hamada A, Miyano H, Watanabe H, et al. Interaction Of Imatinib Mesilate with Human P-Glycoprotein [ J]. The Journal Of Pharmacology And Experimental Therapeutics,2003,307 (2) : 824 - 8. 被引量:1
  • 9Vamvakopoulos JE, Petrov L, Aavik S, et al. Synergistic Suppression of Rat Neointimal Hyperplasia by Rapamyciu and Imatinib Mesylate : Implications for the Prevention of Accelerated Arteriosclerosis [J]. J Vasc Res,2006 43:184 -92. 被引量:1
  • 10Rosasco MA, Moyano MA, MTPizzorno MT, et al. Validation of an HPLC Method for the Determination of Imatinib Mesylate in Pharmaceutical Dosage[ J]. Journal of Liquid Chromatography & Related Technologies,2005,28 (20) :3283 - 92. 被引量:1

共引文献33

同被引文献33

  • 1宋耕,轩菡,王年飞,王小磊,许苗苗,陈振东.甲磺酸伊马替尼的临床应用研究[J].中华临床医师杂志(电子版),2011,5(24):7348-7350. 被引量:7
  • 2陈建斌,黄宗干.小剂量伊马替尼治疗慢性髓细胞白血病急变期患者的临床疗效[J].华西药学杂志,2004,19(5):387-389. 被引量:1
  • 3郑斌,危晴岚,刘茂柏.甲磺酸伊马替尼临床研究概况[J].海峡药学,2006,18(6):78-80. 被引量:12
  • 4Li J,Huang YF, Huang L,et al late and related compounds by Determination of imatinib mesy- field amplified sample stacking with large volume sample injection capillary electrophoresis [ J ]. J Pharm Biomed Anal ,2012,70:26 - 31. 被引量:1
  • 5Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high - performance liquid chromatography - tandem mass spectrometry[ J ]. Ther Drug Monit,2005 ,27 (5) : 634 - 640. 被引量:1
  • 6王竞.甲磺酸伊马替尼胶囊质量标准研究及稳定性研究[D].成都:四川大学硕士学位论文,2013. 被引量:1
  • 7Chinese Pharmacopoeia Commission.Chinese Pharmacopoeia:Part 2(中华人民共和国药典:二部)[S].2010:1301. 被引量:1
  • 8国家食品药品监督管理总局药品审评中心.化学药物制剂研究的技术指导原则[EB/OL].(2007-08-23)[2016.03-07].1attp:llwww.ode.org.cn/zdyz.do?method=largePage&id=2061. 被引量:1
  • 9FDA. Label and Approval History[EB/OL]. [2016-03-07] http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. cfm?fuseaction=Search.Label_ApprovalHistory#1abelinfo. 被引量:1
  • 10Dissolution Methods-Printable List of All Drugs in the Database[EB/OL]. [2016-03-07]. http://www.accessdata.fda. gov/scripts/cder/dissolution/dsp_SearchResults.cfm. 被引量:1

引证文献5

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部